News & Events

Show:
March 22, 2021

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

A late-breaking e-poster and oral presentation provided details of the preclinical findings supporting the company’s development of CRN04894 and CRN04777....

READ MORE
March 12, 2021

ENDO 2021 Presentations Showcase Three Clinical Programs

Details of the improved tablet formulation of paltusotine advancing into Phase 3 studies. Preclinical evidence supporting the development of its...

READ MORE
February 27, 2021

ENDO 2021

Event Date: March 20–23, 2021

READ MORE
February 4, 2021

Lead ACTH Antagonist CRN04894 (Cushing’s, CAH) Enters Phase 1 Study

This study will assess the safety and tolerability of single and multiple doses of CRN04894 and will measure the effect...

READ MORE
February 3, 2021

CRN04777 (Congenital Hyperinsulinism) Advances to Phase 1 Study

Phase 1 study of CRN04777, an oral, nonpeptide somatostatin receptor type 5 (SST5) agonist being developed as a treatment for...

READ MORE
January 27, 2021

10th Annual SVB Leerink Global Healthcare Conference

Event Date: February 24–26, 2021

READ MORE
January 13, 2021

Crinetics Update 39th Annual J.P. Morgan Healthcare Conference

Webcast: Crinetics Pharmaceuticals’ Founder and CEO, Scott Struthers provides 2020 review and 2021 Plans at 39th Annual JP Morgan Healthcare...

READ MORE
January 6, 2021

Crinetics Announces 2021 Plans at J.P. Morgan Healthcare Conference

Scott Struthers, Ph.D., Founder & CEO of Crinetics, presented 2020 update and 2021 plans. Live webcast of the presentation may be...

READ MORE
January 4, 2021

39th Annual J.P. Morgan Healthcare Conference

Event Date: January 11–14, 2021

READ MORE
December 14, 2020

Podcast: Work Continues on New Drugs/Therapies for Pituitary Patients

We wondered how this critically important work for pituitary patients was affected by the pandemic. Dr. Struthers gives us an...

READ MORE